Patents by Inventor Katrina Di Tullio

Katrina Di Tullio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10234450
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: March 19, 2019
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 10209251
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 19, 2019
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Publication number: 20170199181
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9651547
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 16, 2017
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Publication number: 20170023565
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: October 6, 2016
    Publication date: January 26, 2017
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9488663
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 8, 2016
    Assignee: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Patent number: 9140693
    Abstract: This invention relates generally to devices and methods for performing optical and electrochemical assays and, more particularly, to testing devices having an optically readable microspot array and/or an electrochemical detector and to methods of performing microspot arrays and electrochemical assays using such devices. The present invention is particularly useful for performing immunoassays and/or electrochemical assays at the point-of-care.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 22, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Thomas Ewart, Graham Davis, Pierre Emeric, Sergey Gershtein, Smitha Sutrala, Katrina Di Tullio
  • Publication number: 20140273034
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell
  • Publication number: 20140273014
    Abstract: The present invention is directed to methods and devices for amending undiluted and partially diluted urine samples in a manner suitable for performing immunoassays for target analytes, for example NGAL. Generally, the urine sample is treated with reagents including at least one of buffer materials, water soluble proteins, urease, and other interferent mitigants. These reagents control the pH of the urine sample in a manner suitable for immuno-binding reactions and ameliorate interferences, particularly during the detection step.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Abbott Point of Care Inc.
    Inventors: Katrina Di Tullio, G. Bruce Collier, John Lewis Emerson Campbell